We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+82.04%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$3.41B
AUM Growth
+$1.01B
Cap. Flow
-$71.6M
Cap. Flow %
-2.1%
Top 10 Hldgs %
73.51%
Holding
40
New
7
Increased
9
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$105M
2
QURE icon
uniQure
QURE
+$73.3M
3
IMMU
Immunomedics Inc
IMMU
+$61.7M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$23.8M
5
CUE icon
Cue Biopharma
CUE
+$19.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$126M
2
PCRX icon
Pacira BioSciences
PCRX
+$60.9M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.5M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$40.4M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 84.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$7.09B
$11.1M 0.33%
+1,000,000
New +$7.6M
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$10.8M 0.32%
5,500,000
+2,800,000
+104% +$10.5M
FENC icon
28
Fennec Pharmaceuticals
FENC
$331M
$7.17M 0.21%
1,105,999
– –
DCPH
29
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.01M 0.15%
+800,000
New +$38M
ALIM
30
DELISTED
Alimera Sciences
ALIM
$3.15M 0.09%
415,999
-1
-0% -$6
SGEN
31
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$150K ﹤0.01%
+75,000
New +$7.95M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.36B
– –
-887,500
Closed -$31.9M
KOD icon
33
Kodiak Sciences
KOD
$2.54B
– –
-500,000
Closed -$7.19M
PCRX icon
34
Pacira BioSciences
PCRX
$1.03B
– –
-1,600,000
Closed -$60.9M
PTCT icon
35
PTC Therapeutics
PTCT
$5.7B
– –
-684,000
Closed -$23.1M
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$368M
– –
-285,714
Closed -$3.33M
GBT
37
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-1,000,000
Closed -$48.5M
TPTX
38
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-100,000
Closed -$3.76M
TLGT
39
DELISTED
Teligent, Inc
TLGT
– –
-523,121
Closed -$4.97M
MDCO
40
DELISTED
Medicines Co
MDCO
– –
-371,623
Closed -$18.6M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Avoro Capital Advisors held 40 positions worth $3.41B, up 42% from $2.4B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors's Q4 2019 filing shows 7 new, 9 increased, 11 reduced and 9 closed positions. Its largest new stake was Constellation Pharmaceuticals, Inc.: 3,650,000 shares worth $172M. The largest sale was Amarin Corp, an estimated $126M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 88% a quarter earlier.

  • Avoro Capital Advisors's largest Q4 2019 buy was Constellation Pharmaceuticals, Inc.: 3,650,000 shares worth $172M.
  • Avoro Capital Advisors added most to uniQure in Q4 2019, an estimated $73.3M increase.
  • Avoro Capital Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $126M.
  • Avoro Capital Advisors fully exited Pacira BioSciences in Q4 2019, selling an estimated $60.9M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $3.41B portfolio in Q4 2019.
  • Avoro Capital Advisors opened 7 new positions and closed 9 in Q4 2019.
  • Avoro Capital Advisors's portfolio value rose 42% quarter-over-quarter to $3.41B.

Based on Avoro Capital Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.